Performance · Recovery · Longevity

Shopping Cart (0)

Catalogue

Shop

Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).

Research peptides & wellness compounds

Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.

PEG-MGF 5000mcg (UPA Platinum)

Category:
Muscle / GH / Performance
SKU:
TRW-MGF
Price:
R 490.00
{{variant.name}}:
{{opt.name}}
{{opt.value ? '' : opt.name}}
{{opt.value ? '' : opt.name}}
Description

TEST RUN WELLNESS PEG-MGF 5000 | Mechano Growth Factor 5000 mcg Self-Mix Vial

 

PEG-MGF 5000 (PEG-MGF 5000 mcg) – Long-acting Mechano Growth Factor for muscle stem cell activation, accelerated repair, and increased lean volume. Platinum Series. Includes 2 ml bacteriostatic water.

 

Product Overview

PEG-MGF 5000 is a PEG-MGF 5000mcg self-mix vial. Mechano Growth Factor (MGF), also known as IGF-1Ec in humans, is a splice variant of the IGF-1 gene produced locally in muscle tissue in response to mechanical loading and exercise-induced damage.

 

Native MGF is rapidly degraded in circulation with a half-life of approximately 5–7 minutes, which limits its therapeutic utility. PEG-MGF is a pegylated form of MGF, engineered with polyethylene glycol conjugation that shields the peptide from enzymatic degradation and slows renal clearance, extending the half-life from minutes to several hours.

 

This modification enables systemic administration and sustained satellite cell activation.

How PEG-MGF Works: Mechano Growth Factor Satellite Cell Activation Pathway

PEG-MGF acts on muscle stem cells (satellite cells) through a distinct signalling pathway that is separate from the IGF-1 receptor.

 

Research has demonstrated that MGF increases myoblast proliferation even in the presence of anti-IGF-1 receptor antibodies, confirming that its action on satellite cells does not involve the IGF-1 receptor. The MGF E-domain peptide acts as a separate growth/repair factor with a unique signalling pathway, distinct from the mature IGF-1 domain that is cleaved from the same gene product.

 

MGF is upregulated exclusively in response to eccentric exercise and mechanical loading, where it initiates the hypertrophy process by activating the proliferation of satellite cells.

 

These activated satellite cells can then proceed through differentiation and myonuclear accretion, fusing with existing muscle fibres to support repair and growth. Only after the Ec peptide domain has acted and MGF is cleaved, does the mature IGF-1 domain engage the IGF-1 receptor to drive protein synthesis and differentiation.

 

This sequential mechanism — MGF first activating satellite cells, then IGF-1 driving growth — forms the biological basis for the IGF-1 LR3 and PEG-MGF stacking protocol.

 

Body Recomposition Benefits

PEG-MGF promotes favourable body composition changes through satellite cell-mediated muscle repair and hypertrophy. Research has demonstrated that PEG-MGF helps increase the muscle stem cell count, allowing more satellite cells to fuse and become part of adult muscle cells.

 

This mechanism is distinct from traditional anabolic pathways — MGF does not directly grow muscle fibres but enlarges the pool of available satellite cells that can contribute to muscle repair and growth.

 

Animal and cell culture studies indicate that MGF activates satellite cells and increases their proliferation at the expense of differentiation, which may explain the enhancement of the satellite cell pool.

 

Ageing muscle has a declining ability to produce MGF, but administration of the MGF peptide prevents satellite cells from entering senescence and activates reserve progenitor cells to fuse with existing fibres.

 

This makes PEG-MGF particularly valuable in body recomposition protocols for individuals seeking to enhance recovery capacity, support muscle repair from intense training, and increase lean volume over time.

 

PEG-MGF does not produce overnight transformations — typical results timelines show subtle recovery improvements in the first one to two weeks, building into clear strength and size changes between weeks three and eight.

 

Titration Protocol

PEG-MGF is administered via subcutaneous injection. Unlike native MGF, which requires daily intramuscular injection immediately post-workout, the pegylated form’s extended half-life of approximately 48–72 hours allows for less frequent dosing at 2–3 times per week.

 

The standard research protocol is 200 mcg per dose, administered subcutaneously 2–3 times per week. Common dose ranges fall between 200–400 mcg per injection, with 200–300 mcg being optimal for most users.

 

A standard titration schedule is as follows:

· Weeks 1–2 (Ramp-up): 100–200 mcg once weekly — establishes baseline tolerability

 

· Weeks 3–4 (Build): 200 mcg twice weekly — standard working dose

 

· Weeks 5–6 (Peak): 200–400 mcg twice weekly — advanced range for experienced users

 

· Cycle completion: 4–6 weeks on, followed by 2–4 weeks off before repeat cycling

Injections may be administered subcutaneously or intramuscularly.

 

Subcutaneous administration provides systemic satellite cell priming, while intramuscular injection into the trained muscle group immediately post-workout provides localised effects.

 

Beginners should start at 100–200 mcg once per week and assess tolerance before increasing frequency or dose. Increase dose by 50–100 mcg increments if insufficient growth by week four.

 

Combination Therapy

PEG-MGF is most commonly used in combination with IGF-1 LR3 for synergistic muscle growth and recovery:

 

· IGF-1 LR3 + PEG-MGF: This stack is designed to separate the training stimulus from the recovery phase. PEG-MGF is excellent for initiating repair immediately after damage, while IGF-1 LR3 is better for long-term systemic growth.

 

The biological rationale is complementary: MGF splits the cells (activates satellite cell proliferation), while IGF-1 grows them (drives differentiation and protein synthesis).

 

Research-community protocols typically use 100 mcg PEG-MGF twice weekly alongside 50–80 mcg IGF-1 LR3 post-workout. Importantly, IGF-1 LR3 and PEG-MGF should not be injected on the same day, as IGF-1 can compete with MGF for receptor binding and reduce the localized effect.

 

· BPC-157 and TB-500: The combination of PEG-MGF with BPC-157 and TB-500 targets both satellite cell activation and localized tissue repair. BPC-157’s anti-inflammatory and healing properties complement PEG-MGF’s satellite cell-mediated repair mechanisms.

 

· Growth hormone secretagogues (CJC-1295 / Ipamorelin): Stacking with GHRH analogues and ghrelin mimetics provides upstream GH stimulation alongside downstream MGF-mediated satellite cell activation, targeting multiple points in the muscle repair and growth cascade.

All combination approaches should be pursued under professional medical supervision.

 

Clinical Research Record

No human clinical trials have been conducted with PEG-MGF. No registered clinical trials exist for PEG-MGF in any indication, and the peptide has not undergone human safety or efficacy testing in a controlled setting. All available evidence for PEG-MGF is limited almost entirely to animal and cell culture studies.

 

A 2026 review in Frontiers in Endocrinology classified PEG-MGF among compounds with a complete absence of peer-reviewed human studies, supported only by preclinical extrapolation and grey-literature user narratives. Claims that PEG-MGF reliably accelerates recovery or improves body composition in humans remain unproven.

 

The most cited MGF research includes in vitro studies demonstrating that MGF peptide increases myoblast proliferation and retards differentiation, even in the presence of anti-IGF-1 receptor antibodies.

 

One independent laboratory replication found no proliferative effect on primary human myoblasts, a direct replication failure that raises questions about the robustness of the satellite cell activation hypothesis.

 

MGF is not FDA-approved for any indication, and the FDA lists pegylated MGF (PEG-MGF) as nominated but withdrawn after its nomination was withdrawn in April 2026.

 

Technical Specifications

· Product Name: PEG-MGF 5000
· Peptide: PEG-MGF (Pegylated Mechano Growth Factor, IGF-1Ec splice variant)
· Concentration: 5000mcg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Half-life: Approximately 48–72 hours (PEGylated); native MGF approximately 5–7 minutes
· Administration: Subcutaneous or intramuscular injection, 2–3 times per week
· Storage: Lyophilized powder at -20°C for long-term storage or 2–8°C short-term; reconstituted solution at 2–8°C, use within 2–3 weeks; do not freeze reconstituted solution; protect from light
· Supplier: Test Run Wellness (Wellness.testrun)

 

⚕️  Important Medical Notice

Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. PEG-MGF 5000 is intended for use under professional medical supervision. 

Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.